PAG1 Antibody

What is PAG1 and what is its functional significance in cellular signaling?

PAG1, also known as Cbp (Csk-binding protein), is a transmembrane adaptor protein primarily localized to membrane rafts (glycosphingolipid-enriched microdomains). Although PAG1 has a calculated molecular weight of approximately 47 kDa (432 amino acids), it typically migrates at 50-85 kDa on SDS-PAGE gels due to extensive post-translational modifications .

PAG1 functions as a key regulator of Src family kinases (SFKs) by binding and activating Csk (C-terminal Src kinase), the major negative regulator of SFKs. Following tyrosine phosphorylation by SFKs, PAG1 recruits and activates Csk, creating a negative feedback loop that modulates immune cell signaling .

The signaling dynamics of PAG1 vary across different immune cell types:

• In B cells and mast cells: Receptor stimulation (B-cell receptor or FcεRI) leads to increased PAG1 phosphorylation and Csk binding

• In T cells: T cell receptor signaling causes PAG1 dephosphorylation, loss of Csk binding, and increased activation of the SFK Lck

Recent research has revealed PAG1's significance in cancer biology, with evidence that PAG1 expression negatively correlates with survival in multiple human tumors and contributes to tumor growth and immune evasion mechanisms .

What types of PAG1 antibodies are available for research and what are their characteristics?

Several types of PAG1 antibodies are available for research applications, each with distinct properties:

When selecting a PAG1 antibody, researchers should consider several factors:

• Epitope location (cytoplasmic vs. extracellular domains)

• Host species compatibility with your experimental system

• Validated applications and dilution recommendations

• Species cross-reactivity requirements

• Monoclonal vs. polyclonal based on experimental needs

What are the recommended applications and dilutions for PAG1 antibodies?

PAG1 antibodies can be used in various research applications, each requiring specific dilutions and optimization:

Western Blot (WB):

• Proteintech antibody (25029-1-AP): 1:500-1:2000 dilution

• R&D Systems antibody (MAB5285): 1 μg/mL

• Expected molecular weight: 50-85 kDa (can vary by cell type and antibody)

Immunohistochemistry (IHC):

• Proteintech antibody (25029-1-AP): 1:50-1:500 dilution

• Validated positive samples: human ovary cancer tissue

• Recommended antigen retrieval: TE buffer pH 9.0 or citrate buffer pH 6.0

Detection in Cell Lines:

• Validated positive controls: Daudi and Raji human Burkitt's lymphoma cell lines

• For mouse samples: brain tissue has been validated for PAG1 detection

Simple Western:

• R&D Systems antibody (MAB5285): 10 μg/mL

• Sample loading: 0.2 mg/mL of cell lysate

• Expected molecular weight: approximately 76 kDa

It is strongly recommended to titrate each antibody in your specific experimental system to determine optimal conditions. Sample-dependent variations may require adjustment of recommended dilutions .

How should I design Western blot experiments to detect PAG1?

Designing effective Western blot experiments for PAG1 detection requires attention to several key parameters:

Sample Preparation:

• Use appropriate lysis buffers containing phosphatase inhibitors to preserve PAG1's phosphorylation status

• Validated cell lines: Daudi and Raji human Burkitt's lymphoma cells show consistent PAG1 expression

• For tissue samples, mouse brain tissue has been validated for certain antibodies

Gel Electrophoresis and Transfer:

• Use reducing conditions for SDS-PAGE separation

• PVDF membrane is recommended for optimal protein binding and signal

• Recommended separation system: 12-230 kDa range for Simple Western analysis

Detection Protocol:

• Block membrane with appropriate blocking buffer (specific to your antibody)

• Probe with primary antibody at recommended dilution (e.g., 1 μg/mL for MAB5285 or 1:500-1:2000 for 25029-1-AP)

• Wash thoroughly according to standard protocols

• Incubate with appropriate HRP-conjugated secondary antibody (e.g., Anti-Mouse IgG for MAB5285)

• Develop using chemiluminescence detection

Expected Results:

• PAG1 typically appears as bands at 50-85 kDa depending on the cell type and antibody used

• R&D Systems antibody (MAB5285) detects PAG1 at 70-85 kDa in Burkitt's lymphoma cell lines

• Proteintech antibody (25029-1-AP) typically detects bands at 50-60 kDa

• Some heterogeneity in band appearance is expected due to post-translational modifications

Controls:

• Include positive control lysates (Daudi or Raji cells)

• Use appropriate molecular weight markers covering the 50-85 kDa range

• Include loading control (β-actin, GAPDH) to normalize expression levels

Why does PAG1 show discrepancy between calculated and observed molecular weight?

The discrepancy between PAG1's calculated molecular weight (~47 kDa) and its observed migration pattern (50-85 kDa) on SDS-PAGE is a well-documented phenomenon with important implications for research:

Molecular Basis for Anomalous Migration:

• Extensive Post-translational Modifications:

  • PAG1 undergoes multiple tyrosine phosphorylation events, particularly following activation of Src family kinases

  • Additional modifications may include serine/threonine phosphorylation and glycosylation

  • These modifications increase apparent molecular weight and introduce charge variations

• Structural Features:

  • PAG1 contains regions that may affect SDS binding efficiency

  • The transmembrane domain and palmitoylation sites can alter migration behavior

Observed Molecular Weight Variations:

• 70-85 kDa in Daudi and Raji cell lines using R&D Systems antibody

• Approximately 76 kDa in Simple Western analysis

• 50-60 kDa using Proteintech antibody

• Described as an 80 kDa molecule in some literature despite the 47 kDa predicted size

Research Implications:

• When identifying PAG1 in Western blots, look for bands in the 50-85 kDa range rather than at the calculated 47 kDa

• Different antibodies may detect slightly different forms of the protein with varying migration patterns

• Cell activation state can significantly affect the post-translational modification profile and thus the observed molecular weight

• These variations are not artifacts but reflect biologically significant states of the protein

How can I validate the specificity of PAG1 antibodies in my experimental system?

Validating antibody specificity is crucial for ensuring reliable research results. For PAG1 antibodies, consider implementing these validation strategies:

Positive and Negative Controls:

• Use cell lines known to express PAG1 (e.g., Daudi and Raji Burkitt's lymphoma cells)

• For tissue sections, mouse brain tissue has been validated for certain antibodies

• If available, use PAG1 knockout (KO) cell lines or tissues as definitive negative controls

• Compare results with the expected molecular weight range (50-85 kDa)

Multiple Detection Methods:

• Compare results across different techniques (Western blot, IHC, immunofluorescence)

• R&D Systems validated their antibody using both standard Western blot and Simple Western techniques, finding consistent detection of PAG1 at the expected molecular weight

Peptide Competition Assay:

• Pre-incubate the antibody with excess purified PAG1 protein or the immunogen peptide

• This should block specific binding and eliminate or reduce the signal in subsequent assays

• Non-specific binding will remain unaffected

Multiple Antibodies Approach:

• Use antibodies targeting different epitopes of PAG1

• Concordant results with different antibodies suggest specific detection

• The search results describe antibodies targeting various regions of PAG1, including extracellular and cytoplasmic domains

Functional Validation (for Neutralizing Antibodies):

• For neutralizing antibodies, demonstrate functional effects consistent with PAG1 inhibition

• Research has shown that antibodies targeting the extracellular portion of PAG1 can affect its localization to the immune synapse, providing functional validation

RNA Interference or CRISPR Validation:

• Compare antibody signal between wild-type and PAG1-depleted samples

• Demonstrate reduced or absent antibody signal in knockdown/knockout models

• This approach has been used in PAG1 research to validate both antibody specificity and functional studies

How does PAG1 function at the immune synapse and how can antibodies help study this process?

PAG1 plays a critical role at the immune synapse, and antibodies provide valuable tools for investigating this function:

PAG1 Localization at the Immune Synapse:

• PAG1 localizes to the point of contact (immune synapse) between a T cell and antigen-presenting cell (APC)

• This localization is essential for PAG1's function in immune regulation, particularly in the PD-1 pathway

• PAG1 and PD-1 both polarize to the immune synapse during T cell-APC interactions

Experimental Approaches Using Antibodies:

• Confocal Microscopy Studies:

  • Experiments have used PAG-GFP fusion proteins to visualize PAG1 localization

  • Research demonstrated that PAG-GFP becomes enriched at the contact site between Jurkat T cells and Raji B cells

  • By comparing PAG-GFP with Fc-PAG-GFP (mimicking antibody binding), researchers showed that antibody binding could affect PAG1 localization

• Proximity Ligation Assay (PLA):

  • PLA can detect if two proteins are within 40 nm of each other

  • This technique has been used to determine if PAG1 and PD-1 are co-localized following PD-1 ligation

  • The method requires primary antibodies from different host species directed against the two proteins of interest

• Antibody-Mediated Functional Studies:

  • Researchers hypothesized that antibody binding to PAG1 could neutralize its inhibitory function by causing steric hindrance

  • Experiments with Fc-PAG-GFP showed this construct was excluded from the immune synapse more often than regular PAG-GFP

  • This suggested that antibody binding could disrupt PAG1's normal localization and potentially its function

Key Experimental Model:

• PD-L2-overexpressing Raji B cells (as APCs)

• Jurkat T cells (T cell model)

• Superantigen staphylococcal enterotoxin E (SEE) to stimulate T cell receptor signaling

• Combined with antibodies against PAG1 and interaction partners

What is the relationship between PAG1 and cancer immunotherapy?

Recent research has uncovered significant connections between PAG1 and cancer immunotherapy, particularly involving immune checkpoint pathways:

PAG1's Role in Cancer and Immune Evasion:

• PAG1 expression negatively correlates with survival in multiple human tumors

• PAG1 functions as a driver of murine tumor growth and immune evasion

• Murine tumors (colon adenocarcinoma MC38 and melanoma B16) showed limited growth in PAG1 knockout mice

• PAG1 knockout mice exhibited enhanced sensitivity to PD-1 blockade therapy

T Cell-Intrinsic Mechanisms:

• Through T cell adoptive transfer experiments, researchers demonstrated that PAG1's function in tumor immune responses is T cell intrinsic

• PAG1 appears to modulate T cell activation and effector functions in the tumor microenvironment

• PAG1 and PD-1 co-localize at the immune synapse, suggesting functional interaction between these pathways

Implications for Immunotherapy:

Antibody Development for Therapeutic Applications:

• Researchers generated antibodies targeting human PAG1 in mice

• They immunized mice with amino acids 1-16 of human PAG1 combined with keyhole limpet hemocyanin (KLH)

• Hybridoma libraries were created and screened using ELISA and flow cytometry

• These antibodies were tested for their efficacy in binding and neutralizing PAG1 function

How are antibody engineering approaches advancing PAG1 research?

Recent advances in antibody engineering provide new opportunities for PAG1 research, particularly through sequence-based design approaches:

DyAb Technology for Antibody Engineering:

• Sequence-based antibody design and property prediction strategies are emerging as powerful tools

• The DyAb method can generate novel antibody candidates with high binding rates, improving on binding affinity of starting antibodies

• While not specifically applied to PAG1 in the available data, these approaches could be leveraged for developing improved anti-PAG1 antibodies

Key Features of Advanced Antibody Engineering:

• Combines computational design with experimental validation

• Uses machine learning models trained on antibody sequence-function relationships

• Can design antibodies with improved binding affinity, specificity, and other desirable properties

• Implements multi-cycle optimization to progressively enhance antibody performance

Experimental Validation Methods:

• Surface Plasmon Resonance (SPR) for binding kinetics determination

• Protein expression in mammalian cells to ensure proper folding and post-translational modifications

• Structural analysis through crystallography or computational modeling

• Functional assays specific to the target antigen

Application to PAG1 Research:

• These approaches could be applied to develop PAG1 antibodies with:

  • Enhanced binding affinity for improved detection sensitivity

  • Greater specificity to reduce cross-reactivity

  • Modified functional properties (e.g., neutralizing vs. non-neutralizing)

  • Optimized binding to specific regions or conformations of PAG1

Advancing Therapeutic Applications:

• Engineered antibodies could potentially target PAG1 with greater precision

• This could enhance the proposed combination approach with PD-1 blockade

• Advanced binding properties could improve efficacy while reducing off-target effects

• Structural insights from antibody-antigen complexes could inform further therapeutic development

What are common challenges when detecting PAG1 in Western blots and how can they be addressed?

Researchers often encounter specific challenges when detecting PAG1 in Western blots. Here are common issues and their solutions:

Variable Molecular Weight:

• Challenge: PAG1 appears at different molecular weights (50-85 kDa) across different antibodies and cell types

• Solution:

  • Always include positive controls (e.g., Daudi or Raji cell lysates) validated with your specific antibody

  • Be aware of the expected molecular weight range for your particular antibody and cell type (70-85 kDa for R&D Systems, 50-60 kDa for Proteintech)

  • Consider that multiple bands may represent different post-translationally modified forms of PAG1

Weak or Absent Signal:

• Challenge: PAG1 detection may be difficult due to expression level variations or antibody sensitivity

• Solution:

  • Optimize protein loading (20-50 μg of total protein recommended)

  • Adjust antibody concentration (perform a dilution series within recommended ranges)

  • Increase primary antibody incubation time (overnight at 4°C often improves results)

  • Use enhanced chemiluminescence detection systems for greater sensitivity

  • Ensure your lysis buffer effectively extracts membrane-associated proteins

Non-specific Bands:

• Challenge: Some antibodies may detect additional bands besides PAG1

• Solution:

  • Optimize blocking conditions (try both 5% milk and 5% BSA)

  • Increase washing stringency (more washes or higher detergent concentration)

  • Validate with multiple antibodies targeting different PAG1 epitopes

  • Consider using validated positive controls to identify the correct PAG1 band

Post-translational Modifications:

• Challenge: Cell activation state affects PAG1 phosphorylation, potentially altering antibody recognition

• Solution:

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation

  • Consider the activation state of your cells when interpreting band patterns

  • Compare results between resting and activated cells to understand PAG1 dynamics

Experimental Protocol Example:
Based on validated approaches from the literature:

• Prepare lysates from Daudi or Raji cell lines under reducing conditions

• Use PVDF membrane for protein transfer

• Block with appropriate buffer according to antibody specifications

• Probe with recommended antibody concentration (e.g., 1 μg/mL for MAB5285)

• Detect using enhanced chemiluminescence

• Expect bands in the appropriate molecular weight range based on your specific antibody

How can I optimize antibody selection for studying PAG1 in specific cellular contexts?

Selecting the optimal PAG1 antibody for specific cellular contexts requires consideration of multiple factors:

Cell Type Considerations:

• Different cell types may express PAG1 with varying modifications or in different protein complexes

• Antibodies may perform differently across cell types due to epitope accessibility

• When studying immune cells, consider that PAG1 dynamics differ between T cells, B cells, and mast cells

Selection by Experimental Application:

Epitope Considerations:

• Cytoplasmic domain antibodies (e.g., MA1-19289 targeting aa 235-280) access different regions than extracellular domain antibodies

• Phosphorylation-sensitive epitopes may show variable detection depending on cell activation state

• Consider whether your research question requires detection of specific PAG1 domains or modifications

Species Cross-Reactivity:

• Some antibodies are human-specific (e.g., MA1-19289 does not cross-react with mouse, rat, or bovine)

• Others recognize both human and mouse PAG1 (e.g., Proteintech 25029-1-AP)

• Ensure the antibody's species reactivity matches your experimental system

Validation Requirements:

• Prioritize antibodies with validation in your specific application and cell type

• Consider the extent of validation (Western blot bands, IHC images, knockout controls)

• For novel applications, plan appropriate validation experiments

• When possible, use multiple antibodies to confirm results

What is the significance of PAG1's interaction with PD-1 and how can this be studied using antibodies?

The PAG1-PD-1 interaction represents an important nexus in immune regulation with significant implications for cancer immunotherapy:

Molecular Relationship:

• PAG1 and PD-1 both localize to the immune synapse during T cell-APC interactions

• Proximity ligation assay (PLA) has demonstrated that these proteins are within 40 nm of each other following PD-1 ligation

• This spatial relationship suggests a functional connection between PAG1 and the PD-1 inhibitory pathway

Functional Significance:

• PAG1 knockout mice show enhanced sensitivity to PD-1 blockade therapy in tumor models

• This indicates that PAG1 may regulate or interact with the PD-1 pathway

• The combined effect suggests potential synergy between targeting both pathways

Methods to Study PAG1-PD-1 Interaction Using Antibodies:

• Proximity Ligation Assay (PLA):

  • PLA can detect if two proteins are within 40 nm of each other

  • Researchers used this technique with the PD-L2-overexpressing Raji B cell-Jurkat T cell co-culture system

  • The method requires:

    • Primary antibodies from different host species (one for PAG1, one for PD-1)

    • Secondary antibodies with specific DNA tags

    • If proteins are within 40 nm, rolling circle DNA synthesis occurs, producing a detectable signal

• Co-immunoprecipitation:

  • PAG1 antibodies can be used to pull down protein complexes

  • Western blot analysis of the immunoprecipitate can detect co-precipitated PD-1

  • This approach can identify direct or indirect protein interactions

• Confocal Microscopy:

  • Dual staining with antibodies against PAG1 and PD-1

  • Can visualize co-localization at the immune synapse

  • Studies have used PAG-GFP fusion proteins to track localization during immune synapse formation

  • Researchers found that PAG-GFP becomes enriched at the contact site between T cells and APCs

• Functional Studies:

  • Researchers demonstrated that an Fc-PAG-GFP construct (mimicking antibody binding) was excluded from the immune synapse

  • This suggests that antibody binding to PAG1 could disrupt its normal localization and function

  • Such disruption could potentially affect PAG1's interaction with PD-1 and alter signaling outcomes

Experimental Model System:

• PD-L2-overexpressing Raji B cells (as APCs)

• Jurkat T cells (T cell model)

• Superantigen staphylococcal enterotoxin E (SEE) to stimulate T cell receptor signaling

• This system provides a controlled model for studying immune synapse formation and protein interactions

What advanced techniques can be used to characterize PAG1 antibodies beyond standard applications?

Beyond standard applications, several advanced techniques can provide deeper insights into PAG1 antibody characteristics:

Antibody Affinity Extraction (AAE) Combined with Mass Spectrometry:

• AAE is a powerful method for characterizing antibody coverage and specificity

• The process involves using antibodies to capture their target proteins, followed by analysis of the bound fraction

• When combined with mass spectrometry (AAE-MS), this approach can identify specific immunoreactive proteins

• The method can provide both qualitative (protein identity) and quantitative (coverage percentage) information

• This approach could be applied to PAG1 antibodies to assess their coverage of different PAG1 forms or modifications

Two-Dimensional Analysis Methods:

• 2D PAGE combined with Western blotting can separate proteins by both molecular weight and isoelectric point

• This approach can reveal different post-translationally modified forms of PAG1 that might be recognized by specific antibodies

• Virtual 2D-PAGE images can be generated from LC-MS data to visualize all HCPs and antibody-reactive HCPs with MW and pI information

• Such analyses could help characterize the specificity of PAG1 antibodies for different phosphorylated forms

Surface Plasmon Resonance (SPR):

• SPR enables real-time measurement of antibody-antigen binding kinetics

• This technique can determine:

  • Association rate (kon)

  • Dissociation rate (koff)

  • Equilibrium dissociation constant (KD)

• As described in the search results for other antibodies, sensorgrams can be recorded and fit to binding models

• Such analysis would provide quantitative binding parameters for PAG1 antibodies

Epitope Mapping:

• Techniques like peptide arrays or hydrogen-deuterium exchange mass spectrometry can precisely map antibody epitopes

• For PAG1, this could identify exactly which amino acids are recognized by different antibodies

• This information is valuable for understanding antibody specificity and potential cross-reactivity

• It can also inform antibody selection for specific applications (e.g., detecting phosphorylated vs. unphosphorylated forms)

Crystallography and Structural Analysis:

• X-ray crystallography or cryo-electron microscopy of antibody-PAG1 complexes

• These methods provide atomic-level insights into antibody-antigen interactions

• While not specifically mentioned for PAG1 in the search results, structural techniques have been applied to other antibody-antigen complexes

• Structural information could guide further antibody engineering or therapeutic development

How can researchers effectively distinguish between multiple antibodies in complex samples?

Distinguishing between multiple antibodies in complex samples is crucial for multiplex detection, particularly when studying PAG1 alongside other proteins:

Antibody Identification in Research Settings:

• Isotype and Subclass Discrimination:

  • Different antibody isotypes (IgG, IgM, etc.) and subclasses (IgG1, IgG2, etc.) can be distinguished using isotype-specific secondary antibodies

  • For example, if studying PAG1 alongside other proteins, researchers can use:

    • Anti-mouse IgG1 to detect one primary antibody

    • Anti-rabbit IgG to detect another primary antibody

  • This approach allows multiplexing of antibodies from different species or isotypes

• Multiplex Immunoassays:

  • Fluorescence-based detection with spectrally distinct fluorophores

  • Each primary antibody is paired with a secondary antibody conjugated to a different fluorophore

  • This enables simultaneous detection of multiple targets (e.g., PAG1 and its interaction partners)

• Sequential Antibody Detection:

  • For Western blots, antibodies can be stripped and the membrane reprobed

  • This works well when target proteins have distinctly different molecular weights

  • For PAG1 (50-85 kDa), ensure other proteins of interest are in a different molecular weight range

  • Alternatively, cut the membrane to probe different regions with different antibodies

Panel Interpretation Strategies:

When working with antibody panels, especially in complex scenarios like studying multiple proteins or modifications:

• Pattern Recognition Approach:

  • Analyze reaction patterns across different samples or conditions

  • Compare with known positive and negative controls

  • For example, in antibody identification panels, specific reaction patterns can identify particular antibodies

• Elimination and Confirmation Strategy:

  • Systematically rule out possibilities based on reaction patterns

  • Confirm remaining candidates with additional targeted testing

  • This approach is similar to that used in serological antibody identification

• Enzyme Treatment Differential:

  • Some antibody epitopes are sensitive to enzyme treatment while others are not

  • For example, ficin treatment affects certain antibody reactions differently

  • This principle could be applied to distinguish between antibodies with different sensitivities to sample treatment methods

Application to PAG1 Research:

• When studying PAG1 alongside other proteins (e.g., PD-1, Csk, Lck), these approaches can help distinguish specific signals

• For studying different phosphorylated forms of PAG1, phospho-specific antibodies can be used in multiplex approaches

• In co-localization studies, different fluorophores can be used to visualize PAG1 relative to other immune synapse components

How might emerging antibody technologies advance PAG1 research in cancer and immunology?

Emerging antibody technologies are poised to significantly advance PAG1 research with implications for both basic science and therapeutic applications:

Computational Antibody Design:

• Sequence-based antibody design approaches like DyAb can generate novel antibody candidates with enhanced properties

• These methods use machine learning models trained on antibody sequence-function relationships

• Applied to PAG1, such approaches could produce antibodies with:

  • Improved binding affinity for enhanced detection sensitivity

  • Greater specificity for particular PAG1 conformations or modifications

  • Novel functional properties for research or therapeutic applications

Antibody-Based Therapeutic Strategies:

Advanced Imaging Applications:

• Super-resolution microscopy combined with highly specific PAG1 antibodies could provide unprecedented insights into PAG1's localization and dynamics at the immune synapse

• Proximity-based techniques like FRET (Förster Resonance Energy Transfer) could further elucidate PAG1's interactions with binding partners

• These approaches could reveal how PAG1 orchestrates signaling at the molecular level

Customized Specificity Profiles:

• Recent advances in antibody engineering enable design of antibodies with customized specificity profiles

• For PAG1 research, this could enable development of antibodies that:

  • Distinguish between different phosphorylated forms

  • Recognize specific conformational states

  • Target functionally relevant epitopes

• Such tools would provide unprecedented insights into PAG1 biology

Multispecific Antibodies:

• Bispecific or multispecific antibodies targeting PAG1 alongside other relevant proteins could provide new research tools

• These could be used to investigate functional relationships between PAG1 and its binding partners

• In therapeutic contexts, bispecific antibodies could simultaneously target PAG1 and other immune checkpoints

Future PAG1 antibody research is likely to leverage these emerging technologies to deepen our understanding of PAG1's role in immune regulation and cancer biology, potentially leading to novel therapeutic approaches for cancer immunotherapy.